Cargando…
The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction
Therapies that target specific tumor drivers or immune checkpoints are increasingly explored for esophageal cancer patients. This review addresses developments in therapies with targeted anti-human epidermal growth factor receptor 2 (HER2) agents and immune checkpoint inhibitors in patients with sta...
Autores principales: | Valkema, M. J., Mostert, B., Lagarde, S. M., Wijnhoven, B. P. L., van Lanschot, J. J. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852184/ https://www.ncbi.nlm.nih.gov/pubmed/35836094 http://dx.doi.org/10.1007/s13304-022-01327-0 |
Ejemplares similares
-
Carcinosarcoma of the esophago-gastric junction—a case description
por: Włodarczyk, Janusz, et al.
Publicado: (2022) -
The Prognostic Impact of Histology in Esophageal and Esophago-Gastric Junction Adenocarcinoma
por: Fiocca, Roberto, et al.
Publicado: (2021) -
Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review
por: Tondolo, Vincenzo, et al.
Publicado: (2023) -
Isolated Crohn’s disease of the esophagus with esophago-mediastinal fistula formation
por: Wang, Wuping, et al.
Publicado: (2012) -
Anti-angiogenic therapies for advanced esophago-gastric cancer
por: Fontana, Elisa, et al.
Publicado: (2014)